A biotechnology company that spun out of Ohio State University research announced it raised more than $116 million in its latest financing round.
Boston-based Entrada Therapeutics Inc., which was co-founded by an OSU professor, said the investment will support treating people with multiple neuromuscular diseases, including Duchenne muscular dystrophy.
When it was founded in 2018, Entrada raised $59 million, which was the largest amount raised in an initial financing round for an OSU startup.
Click here to read the complete story.
Story excerpt provided by Columbus Business First.
Written by Hayleigh Colombo.
Originally published April 5, 2021.